The FDA approved Lynkuet (elinzanetant) 60 mg capsules for the treatment of moderate to severe hot flashes due to menopause last week. Lynkuet is reportedly the first and only dual neurokinin (NK) targeted therapy, as it is both a neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist. Filling the gap of nonhormonal treatment options… The post Bayer’s Lynkuet approved by FDA for menopausal hot flashes appeared first on Drug Discovery and Development.
